MIRM Q3 2022 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+275.6% YoY

Gross Profit

$16M84.4% margin

Operating Income

-$33M-175.1% margin

Net Income

-$36M-190.1% margin

EPS (Diluted)

$-1.02

QoQ Revenue Growth

+7.4%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$364M

Total Liabilities

$195M

Stockholders' Equity

$169M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$5M	+275.6%
Gross Profit	$16M	$5M	+217.0%
Operating Income	-$33M	-$43M	+23.2%
Net Income	-$36M	-$47M	+24.2%

Revenue Segments

Product

$19M100%